A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

NCT06895512 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

386

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed Multiple Myeloma

Interventions

DRUG: HLX15-IV
DRUG: Darzalex

Sponsor

Shanghai Henlius Biotech